AgMedica Bioscience Inc. Collaborates on Cutaneous T Cell Lymphoma Cell Line (CTCL) Research Paper

For Immediate Release - March 28, 2019

News image

Chatham, Ontario – March 28, 2019 - AgMedica Bioscience Inc. ("AgMedica" or the "Company"), a licensed producer of medicinal cannabis, confirmed that the Company and its strategic partner, MedC Biopharma Corp. (“MedC”) were collaborators on a research paper presented at this year’s 2019 Institute of Cannabis Research Conference (“ICR 2019”), alongside members from world-renowned medical facilities, including the Agricultural Research Organization (“ARO”) Volcani Center (“ARO Volcani”) and Rabin Medical Center, both based in Israel. The 3rd Annual ICR 2019 Conference was held March 23 to 25, 2019 at the Colorado State University in Pueblo, Colorado and attracted more than [900] attendees and researchers from every field of cannabis expertise.  

Presentation Details

AgMedica is extremely pleased to confirm that the continued research and work by members of the MedC team were recognized in this important forum. The Company’s Chief Research Officer, Dr. Owen Van Cauwenberghe, was one of ten co-authors on the presentation given at ICR 2019 by ARO Volcani ’s Professor Hinanit Koltai. This was the only cancer-focused presentation within the conference and was featured in the “New Developments in Medical Cannabis Research” session.  

The presentation, titled “Synergistic Cytotoxic Activity of Cannabinoids from Cannabis sativa Extracts on T Cells Associated with Cutaneous T Cell Lymphoma Cell Lines (CTCL)”, was the outcome of MedC and AgMedica’s collaboration with a team of global researchers. MedC’s and AgMedica’s recognition represents a significant milestone for the Company as it seeks to expand the identification and development of clinically-validated cannabis-derived medicines that can provide substantiated health and wellness benefits – particularly related to oncology.  

The purpose of the study was to identify and characterize extract fractions from cannabis and evaluate the ability of single and combined fractions to effectively act against cancer cells that are associated with leukemia, specifically Cutaneous T-Cell lymphomas (“CTCL”). CTCL is an uncommon type of cancer that occurs in adults aged 40 to 60 and sometimes in children, which can result in life-threatening complications. However, because CTCL is classified as an orphan disease by the FDA, its small market potential has resulted in limited attention by pharmaceutical manufacturers.  Identifying a cure for CTCL is a patient-outcome focused approach, and the objective of the study was to determine whether fractions from cannabis extracts and synergistic combinations with phytocannabinoids may be more highly active against cancer cells and specifically against leukemia.

Study authors include members of the ARO, Volcani Center, Israel (“ARO Volcani”); Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel (“Rabin Medical Center”), and Canadian-based MedC and AgMedica, as outlined below.  

  • Moran Mazuz, ARO Volcani
  • Amir Tiroler, ARO Volcani
  • Lilach Moyal, Rabin Medical Center
  • Emmilia Hodak, Rabin Medical Center
  • Avi Drori, MedC
  • Guy Drori, MedC
  • Owen Van Cauwenberghe, AgMedica
  • Dvora Namdar, ARO Volcani
  • Iris Amitay-Laish, Rabin Medical Center
  • Hinanit Koltai, ARO Volcani

AgMedica / MedC Arrangement

In September 2018, AgMedica entered into an exclusive strategic investment and cooperation agreement with MedC to jointly develop cannabis-derived products and formulations focused on specific clinical targets in oncology, inflammation and psychological disorders by leveraging the exclusive licensing agreements that MedC has with ARO Volcani in specific therapeutic areas. After a decade of research, ARO Volcani holds one of the world's largest IP repositories in pharmaceutical cannabis research and collectively, AgMedica and MedC will focus their experienced management and scientific teams in Canada and Israel to accelerate the development of therapeutic products for human and veterinary use.  

About AgMedica Bioscience Inc.

As a licensed producer of medicinal cannabis, AgMedica is dedicated to becoming a global leader in the development and commercialization of cannabis and cannabis-derived products to support the health and wellness of our clients. We aspire to drive the evolution of the cannabis industry by focusing investment on the development and commercialization of differentiated products in the medicinal, health & wellness and pharmaceutical sectors. For further information, please visit our website at  

For media or other inquiries, please contact:

AgMedica Bioscience Inc.

Sengkee Ahn, MBA, FEA 

Vice President, Investor Relations and International Business Development 

P: 1-844-247-4633 



This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. These risks and uncertainties include, but are not limited to, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.


Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.